Immunotherapy for cholangiocarcinoma: a 2021 update

References

• 1. Kendall T, Verheij J, Gaudio E et al. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 39(Suppl. 1), 7–18 (2019).
  Medline CASGoogle Scholar
• 2. Louis C, Papoutsoglou P, Coulouarn C. Molecular classification of cholangiocarcinoma. Curr. Opin. Gastroenterol. 36(2), 57–62 (2020).
  Medline CASGoogle Scholar
• 3. Banales JM, Marin JJG, Lamarca A et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17(9), 557–588 (2020).
  MedlineGoogle Scholar
• 4. Jusakul A, Cutcutache I, Yong CH et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7(10), 1116–1135 (2017).
  Medline CASGoogle Scholar
• 5. Silva VW, Askan G, Daniel TD et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin. Clin. Oncol. 5(5), 62 (2016).
  MedlineGoogle Scholar
• 6. Piha-Paul SA, Oh DY, Ueno M et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer 147(8), 2190–2198 (2020).
  Medline CASGoogle Scholar
• 7. Weinberg BA, Xiu J, Lindberg MR et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J. Gastrointest. Oncol. 10(4), 652–662 (2019).
  MedlineGoogle Scholar
• 8. Fontugne J, Augustin J, Pujals A et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 8(15), 24644–24651 (2017).
  MedlineGoogle Scholar
• 9. Gani F, Nagarajan N, Kim Y et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 23(8), 2610–2617 (2016).
  MedlineGoogle Scholar
• 10. Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers (Basel) 13(3), 558 (2021).
  Medline CASGoogle Scholar
• 11. Zhai L, Ladomersky E, Lenzen A et al. IDO1 in cancer: a Gemini of immune checkpoints. Cell. Mol. Immunol. 15(5), 447–457 (2018).
  Medline CASGoogle Scholar
• 12. Cousin S, Bellera CA, Guégan JP et al. Regomune: a Phase II study of regorafenib + avelumab in solid tumors — results of the biliary tract cancer (BTC) cohort. J. Clin. Oncol. 39(Suppl. 15), 4096–4096 (2021).
  Google Scholar
• 13. Vogel A, Bathon M, Saborowski A. Immunotherapies in clinical development for biliary tract cancer. Expert Opin. Investig. Drugs 30(4), 351–363 (2021).
  Medline CASGoogle Scholar
• 14. Jenne CN, Kubes P. Immune surveillance by the liver. Nat. Immunol. 14(10), 996–1006 (2013).
  Medline CASGoogle Scholar
• 15. Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann. Hepatol. 18(2), 291–297 (2019).
  Medline CASGoogle Scholar
• 16. Kasper HU, Drebber U, Stippel DL, Dienes HP, Gillessen A. Liver tumor infiltrating lymphocytes: comparison of hepatocellular and cholangiolar carcinoma. World J. Gastroenterol. 15(40), 5053–5057 (2009).
  Medline CASGoogle Scholar
• 17. Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 1(4), 297–311 (2019).
  MedlineGoogle Scholar
• 18. Asahi Y, Hatanaka KC, Hatanaka Y et al. Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma. Surg. Today 50(8), 931–940 (2020).
  Medline CASGoogle Scholar
• 19. Diederichsen AC, Hjelmborg J, Christensen PB, Zeuthen J, Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother. 52(7), 423–428 (2003).
  Medline CASGoogle Scholar
• 20. Goeppert B, Frauenschuh L, Zucknick M et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 109(10), 2665–2674 (2013).
  Medline CASGoogle Scholar
• 21. Job S, Rapoud D, Dos Santos A et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 72(3), 965–981 (2020).
  Medline CASGoogle Scholar
• 22. Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W. Biologics, immunotherapy, and future directions in the treatment of advanced cholangiocarcinoma. Clin. Colorectal Cancer 18(2), 81–90 (2019).
  MedlineGoogle Scholar
• 23. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin. Liver Dis. 34(4), 456–464 (2014).
  Medline CASGoogle Scholar
• 24. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site – when a biomarker defines the indication. N. Engl. J. Med. 377(15), 1409–1412 (2017).
  MedlineGoogle Scholar
• 25. Le DT, Durham JN, Smith KN et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349), 409–413 (2017).
  Medline CASGoogle Scholar
• 26. Lickliter JD, Gan HK, Voskoboynik M et al. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. Drug Des. Devel. Ther. 14, 1177–1189 (2020).
  Medline CASGoogle Scholar
• 27. Kim RD, Chung V, Alese OB et al. A Phase II multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 6(6), 888–894 (2020).
  MedlineGoogle Scholar
• 28. Azad NS, Gray RJ, Overman MJ et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J. Clin. Oncol. 38(3), 214–222 (2020).
  Medline CASGoogle Scholar
• 29. Ueno M, Ikeda M, Morizane C et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, Phase I study. Lancet Gastroenterol. Hepatol. 4(8), 611–621 (2019).
  MedlineGoogle Scholar
• 30. Yarchoan M, Cope L, Anders RA et al. Abstract CT043: a multicenter randomized Phase II trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): a NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. Cancer Res. 80(Suppl. 16), CT043–CT043 (2020).
  Google Scholar
• 31. Ioka T, Ueno M, Oh D-Y et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J. Clin. Oncol. 37(Suppl. 4), 387–387 (2019).
  Google Scholar
• 32. Xie C, Duffy AG, Mabry-Hrones D et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 69(5), 2048–2060 (2019).
  Medline CASGoogle Scholar
• 33. Feng K, Liu Y, Guo Y et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell. 9(10), 838–847 (2018).
  Medline CASGoogle Scholar
• 34. Qin S, Chen Z, Liu Y et al. A Phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J. Clin. Oncol. 37(Suppl. 15), 4074–4074 (2019).
  Google Scholar
• 35. Chen X, Wu X, Wu H et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, Phase II trial. J. Immunother. Cancer 8(2), e001240 (2020).
  MedlineGoogle Scholar
• 36. Liu T, Li W, Yu Y et al. 53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: a preliminary analysis of safety and efficacy of an open-label Phase II clinical study. Ann. Oncol. 31, S261 (2020).
  Google Scholar
• 37. Gou M, Liu Tie E, Yan H et al. PD-1 inhibitors plus nab-paclitaxel with S1 (AS) as first line in patients with advanced biliary tract cancer. J. Clin. Oncol. 38(Suppl. 15), e15195–e15195 (2020).
  Google Scholar
• 38. Arkenau HT, Martin-Liberal J, Calvo E et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, Phase I trial (JVDF). Oncologist 23(12), 1407–e1136 (2018).
  Medline CASGoogle Scholar
• 39. Zhou J, Fan J, Shi G et al. 56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A Phase II clinical trial. Ann. Oncol. 31, S262–S263 (2020).
  Google Scholar
• 40. Yoo C, Oh DY, Choi HJ et al. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer. J. Immunother. Cancer 8(1), e000564 (2020).
  MedlineGoogle Scholar
• 41. Aruga A, Takeshita N, Kotera Y, Okuyama R et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific t-cell response and achieve disease stability in advanced biliary tract cancer. Clin. Cancer Res. 19(8), 2224–2231 (2013).
  Medline CASGoogle Scholar
• 42. Aruga A, Takeshita N, Kotera Y et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. J. Transl. Med. 12, 61 (2014).
  MedlineGoogle Scholar
• 43. Yutani S, Shirahama T, Muroya D et al. Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer Sci. 108(9), 1732–1738 (2017).
  Medline CASGoogle Scholar
• 44. Yoshitomi M, Yutani S, Matsueda S et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp. Ther. Med. 3(3), 463–469 (2012).
  Medline CASGoogle Scholar
• 45. Lepisto AJ, Moser AJ, Zeh H et al. A Phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 6(B), 955–964 (2008).
  Medline CASGoogle Scholar
• 46. Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 19(2), 171–178 (2012).
  MedlineGoogle Scholar
• 47. Matsuyama M, Ishii H, Furuse J et al. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Invest. New Drugs 33(2), 490–495 (2015).
  Medline CASGoogle Scholar
• 48. Kaida M, Morita-Hoshi Y, Soeda A et al. Phase I trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J. Immunother. 34(1), 92–99 (2011).
  Medline CASGoogle Scholar
• 49. Guo Y, Feng K, Liu Y et al. Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24(6), 1277–1286 (2018).
  Medline CASGoogle Scholar
• 50. Benson AB, D'Angelica MI, Abbott DE et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 19(5), 541–565 (2021).
  MedlineGoogle Scholar
• 51. Shen T, Zheng S, Geng L et al. Experience with anti-PD-1 antibody, camrelizumab, monotherapy for biliary tract cancer patients and literature review. Technol. Cancer Res. Treat. 19(1), doi: 10.1177/1533033820979703 (2020).
  Google Scholar
• 52. Tan S, Liu K, Chai Y et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 9(1), 135–139 (2018).
  Medline CASGoogle Scholar
• 53. Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X. Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. Drug Des. Devel. Ther. 12, 2085–2096 (2018).
  Medline CASGoogle Scholar
• 54. Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin. Investig. Drugs 30(4), 343–350 (2021).
  Medline CASGoogle Scholar
• 55. Shimomura A, Fujiwara Y, Kondo S et al. Tremelimumab-associated tumor regression following after initial progression: two case reports. Immunotherapy 8(1), 9–15 (2016).
  CASGoogle Scholar
• 56. Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 11(8), 549–564 (2020).
  MedlineGoogle Scholar
• 57. Feng K, Liu Y, Zhao Y et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a Phase II study. J. Immunother. Cancer 8(1), e000367 (2020).
  MedlineGoogle Scholar
• 58. Sahai V, Griffith KA, Beg MS et al. A multicenter randomized Phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01). J. Clin. Oncol. 38(Suppl. 15), 4582–4582 (2020).
  Google Scholar
• 59. Oh D-Y, Lee K-H, Lee D-W et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC). J. Clin. Oncol. 38(Suppl. 15), 4520–4520 (2020).
  Google Scholar
• 60. Simone V, Brunetti O, Lupo L et al. Targeting angiogenesis in biliary tract cancers: an open option. Int. J. Mol. Sci. 18(2), (2017).
  MedlineGoogle Scholar
• 61. Song IH, Jeong MS, Hong HJ et al. Development of a theranostic convergence bioradiopharmaceutical for immuno-PET based radioimmunotherapy of L1CAM in cholangiocarcinoma model. Clin. Cancer Res. 25(20), 6148–6159 (2019).
  Medline CASGoogle Scholar
• 62. Lin J, Shi W, Zhao S et al. Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): preliminary data and correlation with next-generation sequencing. J. Clin. Oncol. 36(Suppl. 4), 500–500 (2018).
  Google Scholar
• 63. Kwon HC, Roh MS, Oh SY et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18(3), 504–509 (2007).
  MedlineGoogle Scholar
• 64. Park KW, Jung ES, Kim DG et al. ERCC1 Can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma. Cancer Res. Treat. 45(1), 63–69 (2013).
  MedlineGoogle Scholar
• 65. He AR, Weinberg BA, Noel MS et al. Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma. J. Clin. Oncol. 38(Suppl. 15), TPS4659–TPS4659 (2020).
  Google Scholar
• 66. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel) 12(6), 1502 (2020).
  CASGoogle Scholar
• 67. Friedlander M, Meniawy T, Markman B et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, Phase Ia/b trial. Lancet Oncol. 20(9), 1306–1315 (2019).
  Medline CASGoogle Scholar
• 68. Xiong F, Gong J, Wang Q. Olaparib and pembrolizumab treatment for BRCA1-mutated and PD-L1-positive intrahepatic cholangiocarcinoma recurrence and metastasis: a case report. Onco. Targets Ther. 13, 6385–6391 (2020).
  Medline CASGoogle Scholar
• 69. Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5(1), 53 (2017).
  MedlineGoogle Scholar
• 70. Sachdev JC, Hu-Lieskovan S, Patnaik A et al. Phase I/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors. Gynecol. Oncol. 141, 147–148 (2016).
  Google Scholar
• 71. Razak AR, Cleary JM, Moreno V et al. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J. Immunother. Cancer 8(2), e001006 (2020).
  MedlineGoogle Scholar
• 72. Ribas A, Algazi A, Ascierto PA et al. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. Nat. Commun. 11(1), 6262 (2020).
  Medline CASGoogle Scholar
• 73. Lee JW, Zhang Y, Eoh KJ et al. The combination of MEK inhibitor with immunomodulatory antibodies targeting programmed death 1 and programmed death ligand 1 results in prolonged survival in Kras/p53-driven lung cancer. J. Thorac. Oncol. 14(6), 1046–1060 (2019).
  Medline CASGoogle Scholar
• 74. Chen Y, Ma L, He Q, Zhang S, Zhang C, Jia W. TGF-beta1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol. Res. 48, 26 (2015).
  MedlineGoogle Scholar
• 75. David JM, Dominguez C, Mccampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1/TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology 6(10), e1349589 (2017).
  MedlineGoogle Scholar
• 76. Ferris RL, Lenz HJ, Trotta AM et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat. Rev. 63, 48–60 (2018).
  Medline CASGoogle Scholar
• 77. Lan Y, Zhang D, Xu C et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta. Sci. Transl. Med. 10(424), eaan5488 (2018).
  MedlineGoogle Scholar
• 78. Kobayashi M, Sakabe T, Abe H et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J. Gastrointest. Surg. 17(9), 1609–1617 (2013).
  MedlineGoogle Scholar
• 79. Higuchi R, Yamamoto M, Hatori T, Shimizu K, Imai K, Takasaki K. Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. Surg. Today 36(6), 559–562 (2006).
  MedlineGoogle Scholar
• 80. Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science 344(6184), 641–645 (2014).
  Medline CASGoogle Scholar
• 81. Boileve A, Hilmi M, Gougis P et al. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the randomized IMMUNOBIL PRODIGE 57 Phase II trial. Eur. J. Cancer 143, 55–63 (2021).
  Medline CASGoogle Scholar
• 82. Klein O, Kee D, Nagrial A et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a Phase II nonrandomized clinical trial. JAMA Oncol. 6(9), 1405–1409 (2020).
  MedlineGoogle Scholar
• 83. Hong TS, Goyal L, Parikh AR et al. A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): preliminary safety and efficacy. J. Clin. Oncol. 38(Suppl. 4), 547–547 (2020).
  Google Scholar
• 84. Zhou J, Gong J, Cao Y et al. Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): an open-label, dose-escalating, and dose-expansion cohort of Phase Ib trial. J. Clin. Oncol. 39(Suppl. 3), 292–292 (2021).
  Google Scholar
• 85. Kelley RK, Mitchell E, Behr S et al. Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC). J. Clin. Oncol. 36(Suppl. 4), 386–386 (2018).
  Google Scholar
• 86. Sharabi AB, Lim M, Deweese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 16(13), e498–e509 (2015).
  MedlineGoogle Scholar
• 87. Asna N, Livoff A, Batash R et al. Radiation therapy and immunotherapy-a potential combination in cancer treatment. Curr. Oncol. 25(5), e454–e460 (2018).
  Medline CASGoogle Scholar
• 88. Van Bussel MTJ, Awada A, De Jonge MJA et al. A first-in-man Phase I study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours. Br. J. Cancer 124(4), 728–735 (2021).
  Medline CASGoogle Scholar
• 89. Sahai V, Buckley TH, Griffith KA, Zalupski M. A multi-center Phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer. J. Clin. Oncol. 37(Suppl. 15), TPS4154–TPS4154 (2019).
  Google Scholar
• 90. Lv M, Chen M, Zhang R et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 30(11), 966–979 (2020).
  Medline CASGoogle Scholar
• 91. Papadopoulos KP, Harb W, Lu N et al. Phase I study of KN035, a novel fusion anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA. Ann. Oncol. 29, viii405 (2018).
  Google Scholar
• 92. Hu Y, Lin H, Hao M, Zhou Y, Chen Q, Chen Z. Efficacy and safety of apatinib in treatment of unresectable intrahepatic cholangiocarcinoma: an observational study. Cancer Manag. Res. 12, 5345–5351 (2020).
  Medline CASGoogle Scholar
• 93. Ma HS, Poudel B, Torres ER et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol. Res. 7(3), 428–442 (2019).
  Medline CASGoogle Scholar
• 94. Guo J, Sheng X, Si L et al. A Phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma. J. Clin. Oncol. 36(Suppl. 15), 9528–9528 (2018).
  Google Scholar
• 95. Sulkowski PL, Corso CD, Robinson ND et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med. 9(375), eaal2463 (2017).
  MedlineGoogle Scholar
• 96. Shen L, Ciesielski M, Ramakrishnan S et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7(1), e30815 (2012).
  Medline CASGoogle Scholar
• 97. Zheng H, Zhao W, Yan C et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin. Cancer Res. 22(16), 4119–4132 (2016).
  Medline CASGoogle Scholar
• 98. Goyal L, Sirard C, Schrag M et al. Phase I and biomarker study of the Wnt pathway modulator DKN-01 in combination with gemcitabine/cisplatin in advanced biliary tract cancer. Clin. Cancer Res. 26(23), 6158–6167 (2020).
  Medline CASGoogle Scholar
• 99. Zhu Y, Yang J, Xu D et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut 68(9), 1653–1666 (2019).
  Medline CASGoogle Scholar
• 100. Leblond MM, Tille L, Nassiri S et al. CD40 agonist restores the antitumor efficacy of anti-PD1 therapy in muscle-invasive bladder cancer in an IFN I/II-mediated manner. Cancer Immunol. Res. 8(9), 1180–1192 (2020).
  Medline CASGoogle Scholar
• 101. Ma Z, Li H, Liu L. Combining PD-1 inhibitor with VEGF/VEGFR2 inhibitor in chemotherapy: report of a patient with end-stage cholangiocarcinoma and review of literature. Recent Pat. Anticancer Drug Discov. 16(1), 101–107 (2021).
  Medline CASGoogle Scholar
• 102. Schuller A, Doshi A, Cantin S et al. Abstract 4523: inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8⁺ T cells, NK cells, and CD103⁺ dendritic cells in mouse syngeneic tumor models. Cancer Res. 80(Suppl. 16), 4523–4523 (2020).
  Google Scholar
• 103. Javle MM, Bridgewater JA, Gbolahan OB et al. A Phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers. J. Clin. Oncol. 39(Suppl. 3), 311–311 (2021).
  Google Scholar
• 104. Huang RY, Francois A, Mcgray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology 6(1), e1249561 (2017).
  MedlineGoogle Scholar
• 105. Leary R, Gardner RB, Mockbee C, Roychowdhury DF. Boosting abscopal response to radiotherapy with sargramostim: a review of data and ongoing studies. Cureus 11(3), e4276 (2019).
  MedlineGoogle Scholar
• 106. Tian H, Shi G, Wang Q et al. Erratum: Author Correction: A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduct. Target Ther. 4, 31 (2019).
  MedlineGoogle Scholar
• 107. Bloom AC, Bender LH, Tiwary S et al. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncoimmunology 8(10), e1625687 (2019).
  MedlineGoogle Scholar
• 108. Chu H, Du F, Jiang L et al. The efficacy of CIK-based immunotherapies for advanced solid tumors. Technol. Cancer Res. Treat. 16(5), 577–585 (2017).
  Medline CASGoogle Scholar
• 109. Pesce S, Greppi M, Tabellini G et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J. Allergy Clin. Immunol. 139(1), 335–346 e333 (2017).
  Medline CASGoogle Scholar
• 110. Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 20(6), 332–342 (2014).
  Medline CASGoogle Scholar
• 111. Eriksson E, Milenova I, Wenthe J et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin. Cancer Res. 23(19), 5846–5857 (2017).
  Medline CASGoogle Scholar
• 112. Musher BL, Smaglo BG, Abidi W et al. A Phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: an interim report. J. Clin. Oncol. 38(Suppl. 4), 716–716 (2020).
  Google Scholar
• 113. Wu HJ, Chu PY. Role of cancer stem cells in cholangiocarcinoma and therapeutic implications. Int. J. Mol. Sci. 20(17), 4154 (2019).
  Google Scholar
• 114. Krebs MG, Lopez J, El-Khoueiry A et al. Abstract CT026: Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 78(Suppl. 13), CT026–CT026 (2018).
  Google Scholar
• 115. Mertens JC, Fingas CD, Christensen JD et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 73(2), 897–907 (2013).
  Medline CASGoogle Scholar
• 116. Kawamoto M, Umebayashi M, Tanaka H et al. Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. Anticancer Res. 38(5), 2739–2748 (2018).
  Medline CASGoogle Scholar
• 117. Xie Y, Wang Y, Li J et al. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics 8(16), 4305–4320 (2018).
  Medline CASGoogle Scholar
• 118. Zhou G, Sprengers D, Mancham S et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J. Hepatol. 71(4), 753–762 (2019).
  MedlineGoogle Scholar
• 119. Li W, Deng Y, Chu Q, Zhang P. Gut microbiome and cancer immunotherapy. Cancer Lett. 447, 41–47 (2019).
  Medline CASGoogle Scholar
• 120. Bahrambeigi S, Molaparast M, Sohrabi F et al. Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy. Immunol. Lett. 220, 32–37 (2020).
  Medline CASGoogle Scholar
• 121. Pandey A, Stawiski EW, Durinck S et al. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat. Commun. 11(1), 4225 (2020).
  Medline CASGoogle Scholar
• 122. Sadeghlar F, Vogt A, Mohr RU et al. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells. Cancer Immunol. Immunother. 70(5), 1451–1464 (2021).
  Medline CASGoogle Scholar
• 123. Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J. Transl. Med. 12, 294 (2014).
  MedlineGoogle Scholar
• 124. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4), 720–731 (2005).
  Medline CASGoogle Scholar
• 125. Duggan MC, Jochems C, Donahue RN et al. A Phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-alpha-2b in patients with CEA-expressing carcinomas. Cancer Immunol. Immunother. 65(11), 1353–1364 (2016).
  Medline CASGoogle Scholar
• 126. Bota DA, Chung J, Dandekar M et al. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts. CNS Oncol. 7(3), CNS22 (2018).
  CASGoogle Scholar
• 127. Sarivalasis A, Boudousquie C, Balint K et al. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. J. Transl. Med. 17(1), 391 (2019).
  Medline CASGoogle Scholar
• 128. Han S, Lee SY, Wang WW et al. A perspective on cell therapy and cancer vaccine in biliary tract cancers (BTCs). Cancers (Basel) 12(11), 3404 (2020).
  CASGoogle Scholar
• 129. Sangsuwannukul T, Supimon K, Sujjitjoon J et al. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. Int. Immunopharmacol. 89(Pt B), 107069 (2020).
  Medline CASGoogle Scholar
• 130. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J. Gastroenterol. 17(9), 1192–1198 (2011).
  MedlineGoogle Scholar
• 131. Huemer F, Leisch M, Geisberger R et al. Combination strategies for immune-checkpoint blockade and response prediction by artificial intelligence. Int. J. Mol. Sci. 21(8), 2856 (2020).
  CASGoogle Scholar
• 132. Rafiq S, Yeku OO, Jackson HJ et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36(9), 847–856 (2018).
  Medline CASGoogle Scholar
• 133. Thakur A, Scholler J, Schalk DL, June CH, Lum LG. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. J. Cancer Res. Clin. Oncol. 146(8), 2007–2016 (2020).
  Medline CASGoogle Scholar
• 134. Miyazato K, Hayakawa Y. Pharmacological targeting of natural killer cells for cancer immunotherapy. Cancer Sci. 111(6), 1869–1875 (2020).
  Medline CASGoogle Scholar
• 135. Lange S, Lampe J, Bossow S et al. A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Hum. Gene Ther. 24(5), 554–564 (2013).
  Medline CASGoogle Scholar
• 136. Zhu ZB, Chen Y, Makhija SK et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int. J. Oncol. 29(5), 1319–1329 (2006).
  Medline CASGoogle Scholar
• 137. Ahmed J, Chard LS, Yuan M et al. A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery. J. Immunother. Cancer 8(1), e000415 (2020).
  MedlineGoogle Scholar
• 138. Cervera-Carrascon V, Quixabeira DCA, Havunen R et al. Comparison of clinically relevant oncolytic virus platforms for enhancing t cell therapy of solid tumors. Mol. Ther. Oncolytics 17, 47–60 (2020).
  Medline CASGoogle Scholar
• 139. Shi G, Yang Q, Zhang Y et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol. Ther. 27(1), 244–260 (2019).
  Medline CASGoogle Scholar
• 140. Groeneveldt C, Van Hall T, Van Der Burg SH, Ten Dijke P, Van Montfoort N. Immunotherapeutic potential of TGF-beta inhibition and oncolytic viruses. Trends Immunol. 41(5), 406–420 (2020).
  Medline CASGoogle Scholar
• 141. Jarnagin WR, Zager JS, Hezel M et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 13(3), 326–334 (2006).
  Medline CASGoogle Scholar
• 142. Yoshida H, Katayose Y, Unno M et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol. Immunother. 52(2), 97–106 (2003).
  Medline CASGoogle Scholar
• 143. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105–111 (2001).
  Medline CASGoogle Scholar
• 144. Wagner J, Wickman E, Derenzo C, Gottschalk S. CAR T Cell therapy for solid tumors: bright future or dark reality? Mol. Ther. 28(11), 2320–2339 (2020).
  Medline CASGoogle Scholar
• 145. Ribas A, Dummer R, Puzanov I et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(6), 1109–1119 e1110 (2017).
  Medline CASGoogle Scholar
• 146. Patel A, Kaufman HL, Disis ML. Next generation approaches for tumor vaccination. Chin. Clin. Oncol. 6(2), 19 (2017).
  MedlineGoogle Scholar
• 147. Korpics MC, Polley MY, Bhave SR et al. A validated T cell radiomics score is associated with clinical outcomes following multisite SBRT and pembrolizumab. Int. J. Radiat. Oncol. Biol. Phys. 108(1), 189–195 (2020).
  MedlineGoogle Scholar